Inhalation of Low Molecular Weight Heparins as Prophylaxis against SARS-CoV-2-Reference-Cited by-同舟云学术

Inhalation of Low Molecular Weight Heparins as Prophylaxis against SARS-CoV-2

Published:2022-12-20 Issue:6 Volume:13 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Eder Julia¹²,Bermejo-Jambrina Marta¹²,Vlaming Killian E.¹²,Kaptein Tanja M.¹,Zaderer Viktoria³,Kemper E. Marleen⁴,Wilflingseder Doris³^ORCID,Reitsma Sietze⁵,de Bree Godelieve J.²⁶,Cohn Danny M.⁷⁸,Geijtenbeek Teunis B. H.¹²^ORCID

Affiliation:

1. Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

2. Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands

3. Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria

4. Department of Pharmacy and Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

5. Department of Otorhinolaryngology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

6. Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

7. Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

8. Amsterdam Institute of Cardiovascular Sciences, Amsterdam, The Netherlands

Abstract

New SARS-CoV-2 variants of concern and waning immunity demonstrate the need for a quick and simple agent to prevent infection. Low molecular weight heparins (LMWH) have been shown to inhibit SARS-CoV-2 in experimental settings.

Funder

EC | European Research Council

ZonMw

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mbio.02558-22

Reference72 articles.

1. A pneumonia outbreak associated with a new coronavirus of probable bat origin

2. Outbreak of COVID-19: A Detailed Overview and Its Consequences